World Journal of Gastrointestinal Oncology最新文献

筛选
英文 中文
Research status and trends of deep learning in colorectal cancer (2011-2023): Bibliometric analysis and visualization. 结直肠癌深度学习研究现状与趋势(2011-2023):文献计量分析与可视化。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-05-15 DOI: 10.4251/wjgo.v17.i5.103667
Lu-Ying Qi, Bai-Wang Li, Jie-Qiong Chen, Hu-Po Bian, Jing-Nan Xue, Hong-Xing Zhao
{"title":"Research status and trends of deep learning in colorectal cancer (2011-2023): Bibliometric analysis and visualization.","authors":"Lu-Ying Qi, Bai-Wang Li, Jie-Qiong Chen, Hu-Po Bian, Jing-Nan Xue, Hong-Xing Zhao","doi":"10.4251/wjgo.v17.i5.103667","DOIUrl":"10.4251/wjgo.v17.i5.103667","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is the third-most prevalent cancer and the cancer with the second-highest mortality rate worldwide, representing a high public health burden. Deep learning (DL) offers advantages in the diagnosis, identification, localization, classification and prognosis of CRC patients. However, few bibliometric analyses of research hotspots and trends in the field have been performed.</p><p><strong>Aim: </strong>To use bibliometric approaches to analyze and visualize the current research state and development trend of DL in CRC as well as to anticipate future research directions and hotspots.</p><p><strong>Methods: </strong>Datasets were retrieved from the Web of Science Core Collection for the period January 2011 to December 2023. Scimago Graphica (1.0.45), VOSviewer (1.6.20) and CiteSpace (6.3.1) were used to analyze and visualize the nation, institution, journal, author, reference and keyword indicators. Origin (2022) was utilized for plotting, and Excel (2021) was used to construct the tables.</p><p><strong>Results: </strong>A total of 1275 publications in 538 journals from 74 countries and 2267 institutions were collected. The number of annual publications has increased over time. China (371, 29.1%), the United States (265, 20.8%) and Japan (155, 12.2%) contributed significantly to the number of articles published, accounting for 62.1% of the total publications. The United States had the strongest ties to other nations. Sun Yat-sen University in China had the highest number of publications (32). The journal with the most publications was <i>Scientific Reports</i> (34, Q2), whereas <i>Gastrointestinal Endoscopy</i> had the most co-citations (1053, Q1). Kather JN, was the author with the most articles (12) and co-citations (287). The most frequently cited reference was <i>Deep Residual Learning for Image Recognition</i>. Keywords were divided into six clusters, with \"colorectal cancer\" (12.34) having the highest outbreak intensity.</p><p><strong>Conclusion: </strong>This study highlights the current status and most active directions of the use of DL in CRC. This approach has important applications in the identification, diagnosis, localization, classification and prognosis of the disease and will remain a central focus in the future.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 5","pages":"103667"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applications of cryotherapy in premalignant and malignant esophageal disease: Preventing, treating, palliating disease and enhancing immunogenicity? 冷冻疗法在食管癌前和恶性疾病中的应用:预防、治疗、缓解疾病和增强免疫原性?
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-05-15 DOI: 10.4251/wjgo.v17.i5.103746
Laura Sophie Boer, Stefan Nierkens, Bas L A M Weusten
{"title":"Applications of cryotherapy in premalignant and malignant esophageal disease: Preventing, treating, palliating disease and enhancing immunogenicity?","authors":"Laura Sophie Boer, Stefan Nierkens, Bas L A M Weusten","doi":"10.4251/wjgo.v17.i5.103746","DOIUrl":"10.4251/wjgo.v17.i5.103746","url":null,"abstract":"<p><p>Cryotherapy is a treatment modality that uses extreme cold to destroy unwanted tissue through both immediate and delayed cellular injury. This therapy is increasingly being adopted across various medical specialties due to its minimally invasive nature and technological advancements that have been made. In the esophagus, cryotherapy is particularly utilized for the management of Barrett esophagus. It has been demonstrated to be effective and safe with potential benefits, such as a reduction in pain, over radiofrequency ablation. Additionally, it might offer a valuable alternative for patients unresponsive to radiofrequency ablation. Cryotherapy is applied for other conditions as well, including esophageal squamous cell neoplasia and malignant dysphagia. More research is needed to gain understanding of the utility in these conditions. Interestingly, cryotherapy has shown the ability to enhance the host's immune response in reaction to antigens left <i>in situ</i> after treatment. While preclinical data have demonstrated promising results, the immune response is often insufficient to induce tumor regression in the clinical setting. Therefore, there is growing interest in the combination of cryotherapy and immunotherapy where ablation creates an antigen depot, and the immune system is subsequently stimulated. This combination holds promise for the future and potentially opens new doors for a breakthrough in cancer treatment.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 5","pages":"103746"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Computed tomography-based deep learning radiomics model for preoperative prediction of tumor immune microenvironment in colorectal cancer. 基于计算机断层扫描的深度学习放射组学模型在大肠癌术前肿瘤免疫微环境预测中的应用。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-05-15 DOI: 10.4251/wjgo.v17.i5.106103
Chuan Zhou, Yun-Feng Zhang, Zhi-Jun Yang, Yu-Qian Huang, Ming-Xu Da
{"title":"Computed tomography-based deep learning radiomics model for preoperative prediction of tumor immune microenvironment in colorectal cancer.","authors":"Chuan Zhou, Yun-Feng Zhang, Zhi-Jun Yang, Yu-Qian Huang, Ming-Xu Da","doi":"10.4251/wjgo.v17.i5.106103","DOIUrl":"10.4251/wjgo.v17.i5.106103","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a leading cause of cancer-related death globally, with the tumor immune microenvironment (TIME) influencing prognosis and immunotherapy response. Current TIME evaluation relies on invasive biopsies, limiting its clinical application. This study hypothesized that computed tomography (CT)-based deep learning (DL) radiomics models can non-invasively predict key TIME biomarkers: Tumor-stroma ratio (TSR), tumor-infiltrating lymphocytes (TILs), and immune score (IS).</p><p><strong>Aim: </strong>To develop a non-invasive DL approach using preoperative CT radiomics to evaluate TIME components in CRC patients.</p><p><strong>Methods: </strong>In this retrospective study, preoperative CT images of 315 pathologically confirmed CRC patients (220 in training cohort and 95 in validation cohort) were analyzed. Manually delineated regions of interest were used to extract DL features. Predictive models (DenseNet-121/169) for TSR, TILs, IS, and TIME classification were constructed. Performance was evaluated <i>via</i> receiver operating characteristic curves, calibration curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>The DL-DenseNet-169 model achieved area under the curve (AUC) values of 0.892 [95% confidence interval (CI): 0.828-0.957] for TSR and 0.772 (95%CI: 0.674-0.870) for TIME score. The DenseNet-121 model yielded AUC values of 0.851 (95%CI: 0.768-0.933) for TILs and 0.852 (95%CI: 0.775-0.928) for IS. Calibration curves demonstrated strong prediction-observation agreement, and DCA confirmed clinical utility across threshold probabilities (<i>P</i> < 0.05 for all models).</p><p><strong>Conclusion: </strong>CT-based DL radiomics provides a reliable non-invasive method for preoperative TIME evaluation, enabling personalized immunotherapy strategies in CRC management.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 5","pages":"106103"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of machine learning nomograms for predicting survival in stage IV pancreatic cancer: A retrospective study. 预测IV期胰腺癌生存的机器学习图的发展和验证:一项回顾性研究。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-05-15 DOI: 10.4251/wjgo.v17.i5.102459
Kun Huang, Zhu Chen, Xin-Zhu Yuan, Yun-Shen He, Xiang Lan, Chen-You Du
{"title":"Development and validation of machine learning nomograms for predicting survival in stage IV pancreatic cancer: A retrospective study.","authors":"Kun Huang, Zhu Chen, Xin-Zhu Yuan, Yun-Shen He, Xiang Lan, Chen-You Du","doi":"10.4251/wjgo.v17.i5.102459","DOIUrl":"10.4251/wjgo.v17.i5.102459","url":null,"abstract":"<p><strong>Background: </strong>Stage IV pancreatic cancer (PC) has a poor prognosis and lacks individualized prognostic tools. Current survival prediction models are limited, and there is a need for more accurate, personalized methods. The Surveillance, Epidemiology, and End Results (SEER) database offers a valuable resource for studying large patient cohorts, yet machine learning-based nomograms for stage IV PC prognosis remain underexplored. This study hypothesizes that a machine learning-based nomogram can predict cancer-specific survival (CSS) and overall survival (OS) with high accuracy in stage IV PC patients.</p><p><strong>Aim: </strong>To construct and validate a machine learning-based nomogram for predicting survival in stage IV PC patients using real-world data.</p><p><strong>Methods: </strong>Clinical data from stage IV PC patients diagnosed <i>via</i> pathology from 2000 to 2019 were extracted from the SEER database. Patients were randomly divided into a training set and a validation set in a 7:3 ratio. Multivariate Cox proportional hazards, Least Absolute Shrinkage and Selection Operator regression, and Random Survival Forest models were used to identify prognostic variables. A nomogram was constructed to predict CSS and OS at 6, 12, and 18 months. The C-index, receiver operating characteristic curves, and calibration curves were used to evaluate the model's predictive performance.</p><p><strong>Results: </strong>A total of 1662 patients were included (1163 in the training set, 499 in the validation set). The median follow-up times were 4 months [interquartile range (IQR): 1-10 months] for the training set and 4 months (IQR: 1-11 months) for the validation set. Key independent prognostic factors identified included age, race, marital status, tumor location, N stage, grade, surgery, chemotherapy, and liver metastasis. The nomogram accurately predicted OS and CSS at 6, 12, and 18 months, with a C-index of 0.727 (OS) and 0.727 (CSS) in the training set, and 0.719 (OS) and 0.716 (CSS) in the validation set. Calibration curves demonstrated excellent model accuracy.</p><p><strong>Conclusion: </strong>The nomogram developed using age, grade, chemotherapy, surgery, and liver metastasis as predictors can reliably estimate survival outcomes for stage IV PC patients and offers a potential tool for individualized clinical decision-making.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 5","pages":"102459"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significance of serum APE1-AAbs, PTX-3, and miR-486-3p in patients with colorectal cancer undergoing radical surgery. 血清APE1-AAbs、PTX-3、miR-486-3p在大肠癌根治性手术患者中的意义
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-05-15 DOI: 10.4251/wjgo.v17.i5.105192
Hao Wang, Wei Wang
{"title":"Significance of serum APE1-AAbs, PTX-3, and miR-486-3p in patients with colorectal cancer undergoing radical surgery.","authors":"Hao Wang, Wei Wang","doi":"10.4251/wjgo.v17.i5.105192","DOIUrl":"10.4251/wjgo.v17.i5.105192","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Colorectal cancer (CRC) is a common malignant tumor of the digestive tract worldwide, characterized by high incidence and mortality rates.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;To investigate the expression of serum apurinic/apyrimidinic endonuclease 1 autoantibodies (APE1-AAbs), peripheral pentraxin-3 (PTX-3), and miR-486-3p in patients with CRC undergoing radical surgery and their relationship with postoperative recurrence and metastasis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective analysis was conducted on the clinical data of 154 CRC patients who underwent laparoscopic radical surgery in our hospital from January 2022 to January 2024. Patients were followed for one year postoperatively and divided into an occurrence group (&lt;i&gt;n&lt;/i&gt; = 28) and a non-occurrence group (&lt;i&gt;n&lt;/i&gt; = 126) based on whether they experienced recurrence or metastasis. The clinical data and the expression levels of APE1-AAbs, PTX-3, and miR-486-3p were compared between the two groups. Multivariate logistic regression analysis was performed to identify risk factors for postoperative recurrence and metastasis in CRC patients. The relationship of APE1-AAbs, PTX-3, and miR-486-3p with postoperative recurrence and metastasis was analyzed using Spearman correlation analysis. Receiver operating characteristic curves were drawn to evaluate the predictive value of serum APE1-AAbs, PTX-3, and miR-486-3p levels alone and their combination for postoperative recurrence and metastasis in CRC.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The occurrence group had significantly higher proportions of patients with an age ≥ 60 years, lymph node metastasis, stage III disease, poor differentiation, tumor diameter &gt; 5 cm, and higher platelet count, carcinoembryonic antigen, and carbohydrate antigen 19-9 levels than the non-occurrence group (&lt;i&gt;P&lt;/i&gt; &lt; 0.05). The expression levels of APE1-AAbs, PTX-3, and miR-486-3p in the occurrence group were significantly higher than those in the non-occurrence group (&lt;i&gt;P&lt;/i&gt; &lt; 0.05). Multivariate logistic regression analysis showed that lymph node metastasis, stage III disease, poor differentiation, and elevated levels of APE1-AAbs, PTX-3, and miR-486-3p were risk factors for postoperative recurrence and metastasis in CRC patients (odds ratio &gt; 1, &lt;i&gt;P&lt;/i&gt; &lt; 0.05). Spearman correlation analysis revealed that the levels of APE1-AAbs, PTX-3, and miR-486-3p were positively correlated with postoperative recurrence and metastasis in CRC patients (&lt;i&gt;r&lt;/i&gt; = 0.642, 0.653, and 0.631, respectively, &lt;i&gt;P&lt;/i&gt; &lt; 0.05). Receiver operating characteristic curve analysis showed that the area under the curve values for APE1-AAbs, PTX-3, and miR-486-3p levels alone and their combination in predicting postoperative recurrence and metastasis in CRC were 0.764, 0.783, 0.806, and 0.875, respectively, with the combination significantly outperforming individual markers (&lt;i&gt;P&lt;/i&gt; &lt; 0.05).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Serum APE1-AAbs, PTX-3, and miR-486-3p level","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 5","pages":"105192"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Up-regulated programmed cell death protein-1/its ligand 1 expression promotes metabolic dysfunction-associated steatotic liver disease malignant progression. 程序性细胞死亡蛋白1/其配体1表达上调促进代谢功能障碍相关的脂肪变性肝病恶性进展
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-05-15 DOI: 10.4251/wjgo.v17.i5.104842
Min Xu, Tian-Tian Ruan, Hao Tang, Rong-Fei Fang, Wen-Li Sai, Qun Xie, Deng-Fu Yao, Min Yao
{"title":"Up-regulated programmed cell death protein-1/its ligand 1 expression promotes metabolic dysfunction-associated steatotic liver disease malignant progression.","authors":"Min Xu, Tian-Tian Ruan, Hao Tang, Rong-Fei Fang, Wen-Li Sai, Qun Xie, Deng-Fu Yao, Min Yao","doi":"10.4251/wjgo.v17.i5.104842","DOIUrl":"10.4251/wjgo.v17.i5.104842","url":null,"abstract":"<p><p>This editorial focuses on the recent article by Yang <i>et al</i> in the <i>World Journal of Gastrointestinal Oncology</i>, which highlights the role of interlukin-17A in promoting hepatocellular carcinoma (HCC) progression by up-regulated programmed cell death protein-1 (PD-1)/programmed cell death protein ligand-1 (PD-L1) expression. Previous, the high PD-1/PD-L1 level was due to hepatitis virus infection leading to systemic innate immune tolerance and cluster of differentiation 8 + T cells exhaustion, ultimately leading to HCC. Recently, interesting studies have found that the malignant progression of metabolic dysfunction-associated steatotic/fatty liver disease (MASLD/MAFLD), that is former nonalcoholic fatty liver disease, was achieved by up-regulated PD-L1 level that was activated the cGAS-STING pathway under lipid accumulation with mitochondrial DNA overflow and up-regulated PD-1/PD-L1 to promote MASLD malignant transformation <i>via</i> immune escape. These data suggested that PD-1 or PD-L1 should be a promising target for preventing or delaying non-viral liver disease malignant progression except of antiviral therapy for HCC.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 5","pages":"104842"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Switching from messenger RNAs to noncoding RNAs, METTL3 is a novel colorectal cancer diagnosis and treatment target. 从信使rna到非编码rna的转换,METTL3是一种新的结直肠癌诊断和治疗靶点。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-05-15 DOI: 10.4251/wjgo.v17.i5.104076
Jun-Nan Liao, Wen-Juan Ni, Ping-Hui Wu, Ya-Dong Yang, Ying Yang, Wen Long, Mei-Zhen Xie, Xiu-Zhi Zhu, Fu-Hua Xie, Xiao-Min Leng
{"title":"Switching from messenger RNAs to noncoding RNAs, <i>METTL3</i> is a novel colorectal cancer diagnosis and treatment target.","authors":"Jun-Nan Liao, Wen-Juan Ni, Ping-Hui Wu, Ya-Dong Yang, Ying Yang, Wen Long, Mei-Zhen Xie, Xiu-Zhi Zhu, Fu-Hua Xie, Xiao-Min Leng","doi":"10.4251/wjgo.v17.i5.104076","DOIUrl":"10.4251/wjgo.v17.i5.104076","url":null,"abstract":"<p><p>N6-methyladenosine (m6A) modification, one of the most prevalent RNA epigenetic modifications in eukaryotes, constitutes over 60% of all RNA methylation modifications. This dynamic modification regulates RNA processing, maturation, nucleocytoplasmic transport, translation efficiency, phase separation, and stability, thereby linking its dysregulation to diverse physiological and pathological processes. <i>METTL3</i>, a core catalytic component of the methyltransferase complex responsible for m6A deposition, is frequently dysregulated in diseases, including colorectal cancer (CRC). Although <i>METTL3</i>'s involvement in CRC pathogenesis has been documented, its precise molecular mechanisms and functional roles remain incompletely understood. <i>METTL3</i> mediates CRC progression-encompassing proliferation, invasion, drug resistance, and metabolic reprogramming-through m6A-dependent modulation of both coding RNAs and noncoding RNAs. Its regulatory effects are primarily attributed to interactions with key signaling pathways at multiple stages of CRC development. Emerging evidence highlights <i>METTL3</i> as a promising biomarker for CRC diagnosis and prognosis, as well as a potential therapeutic target. By synthesizing recent advances in <i>METTL3</i> research within CRC, this review provides critical insights into novel strategies for clinical diagnosis and targeted therapy.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 5","pages":"104076"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel tumor marker index combining carcinoembryonic antigen and carbohydrate antigen 19-9: New prognostic factor for metastatic colorectal cancer. 结合癌胚抗原和碳水化合物抗原19-9的新型肿瘤标志物指数:转移性结直肠癌的新预后因子。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-05-15 DOI: 10.4251/wjgo.v17.i5.104341
Yusuf Ilhan, Onur Yazdan Balcik, Halil Goksel Guzel, Arif Hakan Onder, Bilgin Demir, Mehmet Nuri Baser, Ibrahim Karadag, Mehmet Fatih Ozbay, Tugrul Burak Genc, Sahnura Uzuntas, Oguz Poyrazoglu, Ismail Beypinar, Yakup Ergun, Banu Ozturk
{"title":"Novel tumor marker index combining carcinoembryonic antigen and carbohydrate antigen 19-9: New prognostic factor for metastatic colorectal cancer.","authors":"Yusuf Ilhan, Onur Yazdan Balcik, Halil Goksel Guzel, Arif Hakan Onder, Bilgin Demir, Mehmet Nuri Baser, Ibrahim Karadag, Mehmet Fatih Ozbay, Tugrul Burak Genc, Sahnura Uzuntas, Oguz Poyrazoglu, Ismail Beypinar, Yakup Ergun, Banu Ozturk","doi":"10.4251/wjgo.v17.i5.104341","DOIUrl":"10.4251/wjgo.v17.i5.104341","url":null,"abstract":"<p><strong>Background: </strong>Metastatic colorectal cancer (mCRC) is a global health challenge with a poor prognosis. Prognostic markers are critical for survival prediction.</p><p><strong>Aim: </strong>To evaluate a novel tumor marker index (TMI) combining carcinoembryonic antigen and carbohydrate antigen 19-9.</p><p><strong>Methods: </strong>This multicenter, retrospective study measured baseline carcinoembryonic antigen and carbohydrate antigen 19-9 levels to calculate a TMI as the geometric mean of values normalized to their upper limits of normal. Receiver operating characteristic curve analysis assessed TMI's prognostic accuracy, and patients were stratified into high-TMI (≥ 1.39) and low-TMI (< 1.39) groups. The primary endpoint was overall survival (OS), with progression-free survival and treatment response as secondary endpoints.</p><p><strong>Results: </strong>The study included 305 mCRC patients with a median follow-up of 22.9 months. The median OS for high-TMI patients was 29.5 months, significantly lower than the 45.6 months observed in the low-TMI group (<i>P</i> = 0.02). The 2-year OS rates for the high- and low-TMI groups were 59.4% and 72.9%, respectively. Median progression-free survival was also shorter for the high-TMI group (14.0 <i>vs</i> 16.0 months, <i>P</i> = 0.84). High TMI is an independent prognostic factor for worse OS.</p><p><strong>Conclusion: </strong>TMI is a simple, cost-effective prognostic tool for mCRC, with high TMI associated with poorer survival outcomes.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 5","pages":"104341"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic value of alpha-fetoprotein and prothrombin induced by vitamin K absence-II in serum, bile, and feces in hepatocellular carcinoma. 血清、胆汁和粪便中维生素K缺失ii诱导的甲胎蛋白和凝血酶原对肝癌的诊断价值。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-05-15 DOI: 10.4251/wjgo.v17.i5.105311
Zi-Jun Chen, Xiang-Kun Wang, Chuang-Ye Han, Yong-Fei He, Tian-Yi Liang, Shu-Tian Mo, Guang-Zhi Zhu, Cheng-Kun Yang, Xin-Ping Ye, Zi-Li Lv, Shi-Fu Pang, Xiao-Dong Chen, Peng Wang, Tao Peng
{"title":"Diagnostic value of alpha-fetoprotein and prothrombin induced by vitamin K absence-II in serum, bile, and feces in hepatocellular carcinoma.","authors":"Zi-Jun Chen, Xiang-Kun Wang, Chuang-Ye Han, Yong-Fei He, Tian-Yi Liang, Shu-Tian Mo, Guang-Zhi Zhu, Cheng-Kun Yang, Xin-Ping Ye, Zi-Li Lv, Shi-Fu Pang, Xiao-Dong Chen, Peng Wang, Tao Peng","doi":"10.4251/wjgo.v17.i5.105311","DOIUrl":"10.4251/wjgo.v17.i5.105311","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the most common pathological type of liver cancer and was the third leading cause of cancer-related deaths worldwide in 2020.</p><p><strong>Aim: </strong>To evaluate the diagnostic potential of key tumor markers in serum, bile, and fecal samples for detecting HCC.</p><p><strong>Methods: </strong>Blood, bile, and fecal samples were collected from patients (<i>n</i> = 265) with HCC and cholecystitis from Guangxi Medical University's First Affiliated Hospital. Immunohistochemistry was performed on 69 HCC samples, and 16S ribosomal RNA sequencing was conducted on 166 fecal samples. Tumor marker cut-off values in bile and feces were determined using the Youden index, while serum biomarkers followed hospital standards. Diagnostic performance was evaluated using receiver operating characteristic analysis.</p><p><strong>Results: </strong>The areas under the curve (AUCs) for distinguishing HCC were 0.898, 0.904, and 0.859 for serum alpha-fetoprotein (AFP), prothrombin induced by vitamin K absence-II (PIVKA-II), and bile AFP, respectively. Serum AFP had the highest diagnostic value (80%) for early-stage HCC. Combination analysis found that bile AFP and serum PIVKA-II achieved the highest AUC of 0.965 (<i>P</i> < 0.001), suggesting that bile AFP may serve as a valuable complementary biomarker, particularly in cases where serum AFP is not significantly elevated. Additionally, bile AFP was positively correlated with <i>Actinomyces</i>, which plays a significant role in promoting tumorigenesis; and was negatively correlated with <i>Faecalibacterium</i>, which was associated with robust anticancer immune responses (<i>P</i> < 0.05). These findings suggest the potential role of gut microbiota in modulating AFP levels and HCC progression.</p><p><strong>Conclusion: </strong>Bile AFP improved the sensitivity of HCC detection, with the combination of bile AFP and PIVKA-II demonstrating the highest AUC for HCC diagnosis. AFP is associated with poorer clinical outcomes.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 5","pages":"105311"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Simvastatin inhibits proliferation and migration, promotes oxidative stress and ferroptosis in colon cancer. 辛伐他汀抑制结肠癌细胞增殖和迁移,促进氧化应激和铁下垂。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-05-15 DOI: 10.4251/wjgo.v17.i5.104522
Ying Liu, Hao Ge, Zhi-Min Fan, Ting Lu, Lei He, Meng Li, Hao-Ran Zhao, Qiang Leng
{"title":"Simvastatin inhibits proliferation and migration, promotes oxidative stress and ferroptosis in colon cancer.","authors":"Ying Liu, Hao Ge, Zhi-Min Fan, Ting Lu, Lei He, Meng Li, Hao-Ran Zhao, Qiang Leng","doi":"10.4251/wjgo.v17.i5.104522","DOIUrl":"10.4251/wjgo.v17.i5.104522","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a major cause of cancer-related mortality, with limited therapeutic options for advanced stages. Simvastatin, primarily used to lower cholesterol, has shown potential as an anticancer agent. It may exert its effects by inhibiting <i>SERPINE1</i>, a protein implicated in CRC progression, and activating the cyclic guanosine monophosphate-protein kinase G (cGMP/PKG) signaling pathway. Given these findings, this study hypothesizes that simvastatin inhibits CRC cell proliferation and migration by downregulating <i>SERPINE1</i> and activating the cGMP/PKG pathway, offering a novel therapeutic strategy for CRC management.</p><p><strong>Aim: </strong>To study the effects of simvastatin on the function of colon cancer cells and to uncover the underlying mechanisms.</p><p><strong>Methods: </strong>NCM460, HCT-116, and SW620 cell lines were used for <i>in vitro</i> experiments with simvastatin at doses of 20 μM, 40 μM, and 80 μM. The Stitch database was used to analyze the target genes of simvastatin, whereas STRING was used to investigate <i>SERPINE1</i> and its related pathways. HCT-116 and SW620 cells were transfected with single-cell RNA sequencing reveals <i>SERPINE1</i> with or without Rp-8-Br-cGMP (a PKG inhibitor). Cell toxicity, proliferation, and migration were evaluated using the cell counting kit-8, colony formation, and Transwell assays, respectively. Apoptosis was analyzed <i>via</i> flow cytometry, and levels of reactive oxygen species (ROS), malondialdehyde (MDA), glutathione (GSH), and ferrous ion (Fe<sup>2+</sup>) were detected using commercial kits. Real-time polymerase chain reaction and western blotting were used to analyze gene expression.</p><p><strong>Results: </strong>Simvastatin dose-dependently inhibited the proliferation and migration of HCT-116 and SW620 cells while promoting apoptosis. It downregulated Ki-67, proliferating cell nuclear antigen, <i>MMP2</i>, and <i>MMP9</i>, and upregulated <i>Bax</i>, particularly at higher doses. Simvastatin increased the ROS, MDA, and Fe<sup>2+</sup> levels while decreasing the GSH levels. It downregulated <i>SLC7A11</i> and ferroportin and upregulated <i>TRF1</i>. <i>SERPINE1</i> was identified as a core target, with related genes enriched in the cGMP/PKG pathway. <i>SERPINE1</i> knockdown increased <i>GUCY1B1</i> and <i>PRKG1</i> levels, decreased cell viability, and altered oxidative stress markers, with the effects being reversed by Rp-8-Br-cGMP.</p><p><strong>Conclusion: </strong>Simvastatin effectively inhibited the proliferation and migration of colon cancer cells and promoted apoptosis through the modulation of key targets, such as <i>SERPINE1</i> and the cGMP/PKG signaling pathway.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 5","pages":"104522"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信